Article Figures & Data
Tables
- Table 1
Genotype and haplotype frequencies of CYP3A4 and CYP3A5 variants in prostate cancer cases and sibling controlsa
Genotype/Haplotype Alleles All Subjectsb Caucasians African-Americans Cases Controls Cases Controls Cases Controls CYP3A4 c *1A/*1A 376 (87%) 402 (86%) 362 (93%) 391 (92%) 11 (29%) 8 (21%) *1A/*1B 39 (9%) 52 (11%) 24 (6%) 34 (8%) 13 (34%) 16 (42%) *1B/*1B 18 (4%) 15 (3%) 4 (1%) 1 (0.2%) 14 (37%) 14 (37%) CYP3A5 c *3/*3 345 (78%) 366 (76%) 337 (85%) 359 (82%) 6 (16%) 5 (13%) *3/*1 78 (18%) 94 (20%) 57 (14%) 75 (17%) 18 (47%) 16 (42%) *1/*1 17 (4%) 20 (4%) 3 (0.8%) 3 (0.7%) 14 (37%) 17 (45%) CYP3A4/CYP3A5 d *1A/*3 738 (85%) 798 (85%) 710 (91%) 769 (90%) 21 (28%) 22 (29%) *1A/*1 53 (6%) 58 (6%) 38 (5%) 47 (6%) 14 (18%) 10 (13%) *1B/*1 58 (7%) 73 (8%) 24 (3%) 31 (4%) 32 (42%) 40 (53%) *1B/*3 17 (2%) 9 (1%) 8 (1%) 5 (0.6%) 9 (12%) 4 (5%) -
a Frequencies are calculated from the total number of samples successfully genotyped for each variant.
-
b All subjects include 8 Hispanics (4 cases and 4 controls) and 2 Asian-Americans (1 cases and 1 control).
-
c Counts are for the number of individuals.
-
d Counts are for the number of haplotypes.
-
- Table 2
Family-based associations between CYP3A4 and CYP3A5 genotypes and risk of prostate cancer among cases and sibling controls
Genotype OR (95% CIs), Pa No stratification Stratified by disease aggressivenessb Low High CYP3A4 *1A/*1A 1.0 (referent) 1.0 1.0 All Subjects*1A/*1B or *1B/*1B 0.76 (0.48–1.20), 0.24 0.20 (0.07–0.60), 0.004 1.32 (0.77–2.27), 0.31 Caucasians*1A/*1B or *1B/*1B 0.83 (0.48–1.42), 0.49 0.08 (0.01–0.49), 0.006 1.91 (1.02–3.57), 0.04 African-Americans*1A/*1B or *1B/*1B 0.61 (0.27–1.36), 0.23 0.66 (0.16–2.65), 0.56 0.49 (0.17–1.43), 0.19 CYP3A5 *3/*3 1.0 (referent) 1.0 1.0 All Subjects*3/*1 or *1/*1 0.73 (0.51–1.05), 0.09 0.45 (0.25–0.82), 0.009 1.10 (0.68–1.77), 0.69 Caucasians*3/*1 or *1/*1 0.71 (0.49–1.04), 0.08 0.42 (0.22–0.78), 0.006 1.16 (0.70–1.91), 0.56 African-Americans*3/*1 or *1/*1 1.00 (0.29–3.52), 1.00 0.92 (0.10–8.69), 0.94 0.70 (0.08–5.75), 0.74 -
a Adjusted for age.
-
b Cases and their brothers stratified by tumor aggressiveness of affected brother. Low aggressiveness: Gleason <7, and T category <T2c. High aggressiveness: Gleason ≥7, or T category ≥T2c.
-
- Table 3
Family-based associations between CYP3A4 and CYP3A5 haplotypes and risk of prostate cancer among cases and sibling controls
Haplotype (CYP3A4/CYP3A5) ORs, 95% CIs, Pa No Stratification Stratified by disease aggressivenessb Low High All Subjects *1A/*3 1.0 (referent) 1.0 1.0 *1A/*1 0.90 (0.60–1.34), 0.60 0.62 (0.33–1.16), 0.13 1.17 (0.70–1.98), 0.55 *1B/*1 0.65 (0.41–1.02), 0.06 0.22 (0.09–0.53), 0.0007 1.05 (0.60–1.82), 0.87 *1B/*3 2.91 (1.36–6.23), 0.006 4.51 (0.64–31.74), 0.13 3.15 (1.18–8.37), 0.02 Caucasians *1A/*3 1.0 1.0 1.0 *1A/*1 0.76 (0.48–1.21), 0.25 0.62 (0.31–1.25), 0.18 0.92 (0.51–1.65), 0.77 *1B/*1 0.76 (0.44–1.33), 0.34 0.07 (0.01–0.51), 0.009 1.80 (0.95–3.43), 0.07 *1B/*3 2.36 (0.85–6.54), 0.10 3.93 (0.47–32.82), 0.21 4.18 (0.71–24.79), 0.11 African-Americans *1A/*3 1.0 1.0 1.0 *1A/*1 1.24 (0.49–3.18), 0.65 2.49 (0.29–21.1), 0.40 0.83 (0.16–4.19), 0.82 *1B/*1 0.63 (0.26–1.56), 0.32 1.80 (0.12–28.0), 0.68 0.38 (0.09–1.54), 0.17 *1B/*3 4.08 (1.35–12.4), 0.01 c 3.05 (1.22–7.61), 0.02 -
a Adjusted for age.
-
b Cases and their brothers stratified by tumor aggressiveness of affected brother. Low aggressiveness: Gleason <7, and T category <T2c. High aggressiveness: Gleason ≥7, or T category ≥T2c.
-
c Extremely unstable results due to small sample size.
-
Volume 12, Issue 9
